Could a probiotic fight anal cancer in HIV patients?
NCT ID NCT06949800
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a probiotic called EXE-346 can help treat anal high-grade squamous intraepithelial lesions (HSIL) and reduce persistent high-risk HPV infection in people living with HIV. The trial will enroll 90 participants who will take the probiotic or a placebo daily. The goal is to see if the probiotic can shrink or eliminate precancerous lesions and clear the virus, potentially preventing anal cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EXE-346 Probiotic
What this could lead to
If it works, this could offer a simple probiotic treatment to reduce anal precancer and HPV infection in people with HIV.
What could go wrong
This is an early phase 2 trial with only 90 participants, so results may not be conclusive. The probiotic may not effectively clear lesions or HPV, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Puerto Rico Comprehensive Cancer Center
San Juan, 00936, Puerto Rico
Contact